FDA OKs Vivus Weight Drug Qsymia After Nod To Rival Arena

Law360, New York (July 17, 2012, 10:17 PM EDT) -- The U.S. Food and Drug Administration on Tuesday approved Mountain View, Calif.-based drugmaker Vivus Inc.’s weight-loss drug Qsymia, weeks after approving rival Arena Pharmaceuticals Inc.’s weight-loss treatment Belviq.

The FDA approved Qsymia, a combination of weight-loss drug phentermine and seizure and migraine drug topiramate, as a weight-loss supplement that like Belviq, or lorcaserin hydrochloride, can be taken by obese adults as well overweight patients with other weight-related health problems including high blood pressure, type 2 diabetes and high cholesterol.

The approvals follow years of stigma against...
To view the full article, register now.